Start Midwest, LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$608,379	42
2024	Research	$124,758	3
2021	Research	$90,054	8

Breakdown

Who paid Research payments · program years 2021–2025

Mitsubishi Tanabe Pharma America, Inc. $301,282 4 payments
Merck Sharp & Dohme Corporation $173,400 2 payments
Stemline Therapeutics Inc. $157,999 20 payments
AstraZeneca Pharmaceuticals LP $93,000 2 payments
Gilead Sciences, Inc. $90,054 8 payments
BioNTech SE $7,457 17 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer $157,999 20 payments
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam $139,772 1 payment
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors $124,520 1 payment
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam $96,453 1 payment
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam $50,536 1 payment
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors $48,880 1 payment
A Phase I II Open label Dose Escalation and Dose Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD6621 a T Cell engaging Antibody That Targets STEAP2 CD3 and CD8 in Adult Participants With Metastatic Prostate Cancer $46,500 1 payment
A Phase I II Open label Dose Escalation and Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD6750 a CD8 Guided IL2 Agent Alone and in Combination With Other Anticancer Agents in Participants with Select Advanced or Metastatic Solid Tumors $46,500 1 payment
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies $28,815 1 payment
A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS 3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors $28,815 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.